Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers<subtitle>A pooled analysis of randomized trials</subtitle>

Kristina A. Bryant; Jodie McVernon; Colin D. Marchant; Terry Nolan; Gary S. Marshall; Peter Richmond; Helen Marshall; Michael Nissen; Stephen B. Lambert; Emmanuel Aris; Narcisa Mesaros; Jacqueline M. Miller

doi:10.4161/hv.20357

Human Vaccines & Immunotherapeutics (Aug 2012)

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers<subtitle>A pooled analysis of randomized trials</subtitle>

Kristina A. Bryant,
Jodie McVernon,
Colin D. Marchant,
Terry Nolan,
Gary S. Marshall,
Peter Richmond,
Helen Marshall,
Michael Nissen,
Stephen B. Lambert,
Emmanuel Aris,
Narcisa Mesaros,
Jacqueline M. Miller

Affiliations

Kristina A. Bryant: University of Louisville; Louisville, KT USA
Jodie McVernon: Vaccine & Immunisation Research Group, Murdoch Children's Research Institute and University of Melbourne; Melbourne, VIC Australia
Colin D. Marchant: Boston University Medical Center; Boston, MA USA
Terry Nolan: Vaccine & Immunisation Research Group, Murdoch Children's Research Institute and University of Melbourne; Melbourne, VIC Australia
Gary S. Marshall: University of Louisville; Louisville, KT USA
Peter Richmond: University of Western Australia School of Paediatrics and Child Health, Telethon Institute for Child Health Research, and Princess Margaret Hospital for Children; Perth, Australia
Helen Marshall: School of Paediatrics and Reproductive Health; University of Adelaide, Adelaide; SA Australia
Michael Nissen: Queensland Paediatric Infectious Diseases Laboratory; Queensland Children’s Medical Research Institute; Royal Children’s Hospital and The University of Queensland; Brisbane, QLD Australia
Stephen B. Lambert: Queensland Paediatric Infectious Diseases Laboratory; Queensland Children’s Medical Research Institute; Royal Children’s Hospital and The University of Queensland; Brisbane, QLD Australia
Emmanuel Aris: GlaxoSmithKline Biologicals; Wavre, Belgium
Narcisa Mesaros: GlaxoSmithKline Biologicals; Wavre, Belgium
Jacqueline M. Miller: GlaxoSmithKline Biologicals; King of Prussia, PA USA

DOI: https://doi.org/10.4161/hv.20357
Journal volume & issue: Vol. 8, no. 8
pp. 1036 – 1041

Abstract

Read online

A pooled analysis was conducted of 1257 toddlers who received a fourth dose of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) or Hib conjugate vaccine (Hib polysaccharide conjugated to N. meningitidis outer membrane protein) coadministered with measles-mumps-rubella (MMR) and varicella (VAR) vaccines (NCT00134719/NCT00289783). Noninferiority of immunological responses to MMR and VAR was demonstrated between groups and incidences of MMR- and VAR-specific solicited symptoms were similar, indicating that HibMenCY-TT can be coadministered with MMR and VAR.

Published in Human Vaccines & Immunotherapeutics

ISSN: 2164-5515 (Print); 2164-554X (Online)
Publisher: Taylor & Francis Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy; Medicine: Therapeutics. Pharmacology
Website: https://www.tandfonline.com/journals/khvi

About the journal

Abstract

Keywords